Patents by Inventor Peter R. Oeltgen
Peter R. Oeltgen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7705119Abstract: Polypeptides, compositions, and methods for treating shock are described. A isolated polypeptide, Deltorphin-E, can be administered without concomitant fluid resuscitation, before, concurrently with, or after the onset of shock or the occurrence of an event that creates a risk of shock. Deltorphin-E can be administered in accordance with the method as part of a preconditioning strategy, which reduces the extent of ischemic injury. Deltorphin-E can be used in preparation for planned ischemia or in a prophylactic manner in anticipation of further ischemic events.Type: GrantFiled: June 6, 2007Date of Patent: April 27, 2010Assignee: University of Kentucky Research FoundationInventors: Peter R. Oeltgen, Meera Govindaswami
-
Patent number: 7335642Abstract: A method of modulating cytokine mediated hepatic injury by administering compound-D SEQ ID NO:1 to a mammal. A concentration of the compound in the range of about 0.5 mg/kg to about 20 mg/kg in a physiologically acceptable formulation blocks a cytokine cascade. A therapeutic method of modulating cytokine mediated acute inflammatory, trauma induced and toxin induced hepatic injury, particularly via tumor necrosis factor modulation, is thus disclosed.Type: GrantFiled: March 22, 2005Date of Patent: February 26, 2008Assignee: University of Kentucky Research FoundationInventors: Peter R. Oeltgen, Paul D. Bishop, Craig J. McClain, Shirish Barve
-
Patent number: 7060792Abstract: A compound and method for using the compound to reduce injury associated with ischemia and reperfusion of mammalian organs such as the heart. The compound, either Deltorphin A and/or Dermorphin H, may be administered as part of a preconditioning strategy which reduces the extent of injury and improves organ function following cessation and restoration of blood flow. The compound may be used in preparation for planned ischemia or in a prophylactic manner in anticipation of further ischemic events.Type: GrantFiled: May 31, 2005Date of Patent: June 13, 2006Assignees: University of Kentucky Research Foundation, ZymogeneticsInventors: Peter R. Oeltgen, Paul D. Bishop, Mark S. Kindy, Juan A. Sanchez
-
Patent number: 6967192Abstract: Peptide P, having the amino acid sequence Tyr-D-Ala-Phe-Ala-Asp-Val-Ala-Ser-Thr-Ile-Gly-Asp-Phe-His-Ser-Ile-NH2-SEQ ID NO:1, is useful to treat ischemia.Type: GrantFiled: March 11, 2003Date of Patent: November 22, 2005Assignee: University of Kentucky Research FoundationInventors: Peter R. Oeltgen, Mark S. Kindy
-
Patent number: 6900178Abstract: A compound and method for using the compound to reduce injury associated with ischemia and reperfusion of mammalian organs such as the heart. The compound, either Deltorphin A and/or Dermorphin H, may be administered as part of a preconditioning strategy which reduces the extent of injury and improves organ function following cessation and restoration of blood flow. The compound may be used in preparation for planned ischemia or in a prophylactic manner in anticipation of further ischemic events.Type: GrantFiled: September 6, 2001Date of Patent: May 31, 2005Assignee: University of Kentucky Research FoundationInventors: Peter R. Oeltgen, Paul D. Bishop, Mark S. Kindy, Juan A. Sanchez
-
Patent number: 6875742Abstract: A method of modulating cytokine mediated hepatic injury by administering compound-D SEQ ID NO:1 to a mammal. A concentration of the compound in the range of about 0.5 mg/kg to about 20 mg/kg in a physiologically acceptable formulation blocks a cytokine cascade. A therapeutic method of modulating cytokine mediated acute inflammatory, trauma induced and toxin induced hepatic injury, particularly via tumor necrosis factor modulation, is thus disclosed.Type: GrantFiled: October 5, 2001Date of Patent: April 5, 2005Assignees: ZymoGenetics, Inc., University of Kentucky Research FoundationInventors: Peter R. Oeltgen, Paul D. Bishop, Craig J. McClain, Shirish Barve
-
Publication number: 20030211998Abstract: Peptide P, having the amino acid sequence Tyr-D-Ala-Phe-Ala-Asp-Val-Ala-Ser-Thr-Ile-Gly-Asp-Phe-Phe-His-Ser-Ile-NH2-SEQ ID NO:1, is useful to treat ischemia.Type: ApplicationFiled: March 11, 2003Publication date: November 13, 2003Applicant: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATIONInventors: Peter R. Oeltgen, Mark S. Kindy
-
Patent number: 6645938Abstract: A compound and method for using compound-D SEQ ID NO:1 to reduce injury associated with ischemia and reperfusion of mammalian organs such as the heart. The compound may be administered as part of a preconditioning strategy which reduces the extent of injury and improves organ function following cessation and restoration of blood flow. The compound may be used in preparation for planned ischemia or in a prophylactic manner in anticipation of further ischemic events.Type: GrantFiled: January 10, 2001Date of Patent: November 11, 2003Assignees: ZymoGenetics, Inc., University of Kentucky Research FoundationInventors: Peter R. Oeltgen, Paul D. Bishop, Mark S. Kindy, Juan A. Sanchez
-
Publication number: 20030109433Abstract: A compound and method for using the compound to reduce injury associated with ischemia and reperfusion of mammalian organs such as the heart. The compound, either Deltorphin A and/or Dermorphin H, may be administered as part of a preconditioning strategy which reduces the extent of injury and improves organ function following cessation and restoration of blood flow. The compound may be used in preparation for planned ischemia or in a prophylactic manner in anticipation of further ischemic events.Type: ApplicationFiled: September 6, 2001Publication date: June 12, 2003Inventors: Peter R. Oeltgen, Paul D. Bishop, Mark S. Kindy, Juan A. Sanchez
-
Patent number: 6544950Abstract: Peptide P, having the amino acid sequence Tyr-D-Ala-Phe-Ala-Asp-Val-Ala-Ser-Thr-Ile-Gly-Asp-Phe-Phe-His-Ser-Ile-NH2, is useful to treat ischemia.Type: GrantFiled: December 6, 2001Date of Patent: April 8, 2003Assignee: University of Kentucky Research FoundationInventors: Peter R. Oeltgen, Mark S. Kindy
-
Publication number: 20020103124Abstract: A method of modulating cytokine mediated hepatic injury by administering compound-D SEQ ID NO: 1 to a mammal. A concentration of the compound in the range of about 0.5 mg/kg to about 20 mg/kg in a physiologically acceptable formulation blocks a cytokine cascade. A therapeutic method of modulating cytokine mediated acute inflammatory, trauma induced and toxin induced hepatic injury, particularly via tumor necrosis factor modulation, is thus disclosed.Type: ApplicationFiled: October 5, 2001Publication date: August 1, 2002Applicant: University of Kentucky Research FoundationInventors: Peter R. Oeltgen, Paul D. Bishop, Craig J. McClain, Shirish Barve
-
Publication number: 20020055468Abstract: A compound and method for using compound-D SEQ ID NO:1 to reduce injury associated with ischemia and reperfusion of mammalian organs such as the heart. The compound may be administered as part of a preconditioning strategy which reduces the extent of injury and improves organ function following cessation and restoration of blood flow. The compound may be used in preparation for planned ischemia or in a prophylactic manner in anticipation of further ischemic events.Type: ApplicationFiled: January 10, 2001Publication date: May 9, 2002Inventors: Peter R. Oeltgen, Paul D. Bishop, Mark S. Kindy, Juan A. Sanchez
-
Patent number: 6380164Abstract: A method of modulating cytokine mediated hepatic injury by administering deltorphins to a mammal. Deltorphin I SEQ ID NO:1, deltorphin II SEQ ID NO:2 or combinations of deltorphins I SEQ ID NO:1 and II SEQ ID NO:2 may be administered. A deltorphin concentration in the range of about 0.5 mg/kg to about 20 mg/kg in a physiologically acceptable formulation blocks a cytokine cascade in a murine model of septic shock. A therapeutic method of modulating cytokine mediated acute inflammatory, trauma induced and toxin induced hepatic injury, particularly via tumor necrosis factor modulation, is thus disclosed.Type: GrantFiled: January 23, 2001Date of Patent: April 30, 2002Assignees: University of Kentucky Research Foundation, ZymoGeneticsInventors: Peter R. Oeltgen, Craig J. McClain, Shirish Barve, Paul D. Bishop
-
Patent number: 6316411Abstract: A compound and method for using the compound to reduce injury associated with ischemia and reperfusion of mammalian organs such as the heart. The compound may be administered as part of a preconditioning strategy which reduces the extent of injury and improves organ function following cessation and restoration of blood flow. The compound may be used in preparation for planned ischemia or in a prophylactic manner in anticipation of further ischemic events.Type: GrantFiled: January 4, 2000Date of Patent: November 13, 2001Assignees: University of Kentucky Research Foundation, ZymoGeneticsInventors: Peter R. Oeltgen, Paul D. Bishop, Mark S. Kindy, Juan A. Sanchez
-
Patent number: 6294519Abstract: A method for treating ischemia by administering deltorphins to a mammal. Deltorphin I SEQ ID NO:1, delntorphin II SEQ ID NO:2 or combinations of deltorphins I SEQ ID NO:1 and II SEQ ID NO:2 may be administered. A deltorphin concentration of about 0.5-20 mg/kg body weight, or alternatively a lower concentration of about 1-1000 &mgr;g/kg body weight of the mammal in a physiologically acceptable formulation is administered up to four hours after an ischemic episode. Deltorphins may also be administered prior to or concurrently with onset of ischemia. Cerebral or spinal cord ischemia or ischemic heart disease may be treated using the method of the invention.Type: GrantFiled: October 31, 2000Date of Patent: September 25, 2001Assignees: University of Kentucky Research Foundation, ZymoGeneticsInventors: Peter R. Oeltgen, Mark S. Kindy, Paul D. Bishop